Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Smaio S.A. is a company specializing in the development and marketing of precision medical devices, particularly in the field of orthopedic surgery. Its primary function is to offer innovative solutions that enhance surgical outcomes and safety for both practitioners and patients. Notable features of Smaio's offerings include surgical planning software and highly precise instrumentation, which are integral to improving surgical precision and reducing operative time. The company's products impact the healthcare and medical technology sectors, providing essential tools that address the evolving needs of modern surgical practices. Smaio S.A.'s operations contribute significantly to the advancement of medical procedures, showcasing its commitment to facilitating better healthcare outcomes. Its presence in the market underscores the importance of technology-driven solutions in medical advancements, cementing its role as a key player in the orthopedic device industry.
The business is unprofitable at the operating level (-28.68% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 66.7% YoY with margins expanding 29.2pp.
Negative free cash flow of -€1M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
€9M
▲ +66.7% YoY
Net Income (TTM)
-€2M
▲ +5.1% YoY
Op. Margin
-28.68%
▲ +29.2pp YoY
ROIC
-20.72%
▲ +2.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€1M
▲ +55.8% YoY
Op. Cash Flow (TTM)
€264K
▲ +118.4% YoY
Net Debt
-€987K
Net Cash Position
Cash & Equiv.
€6M
3Y CAGR: +55.4%
Continue Research